MR-guided Non-invasive Brain Glioma Typing
Abstract
This study presents a machine learning approach for non-invasive glioma typing using MRI data. We develop classifiers that can predict tumor molecular subtypes from imaging features, supporting clinical decision-making in neurosurgery.
Background
The 2016 and 2021 updates to the WHO classification of central nervous system tumors fundamentally changed how gliomas are categorized. Rather than relying solely on histological appearance, the modern classification integrates molecular markers -- most notably IDH mutation status and 1p/19q codeletion -- into the diagnostic criteria. These molecular subtypes carry distinct prognostic and therapeutic implications: IDH-mutant gliomas, for instance, are associated with significantly longer survival compared to IDH-wildtype tumors of the same histological grade, and 1p/19q-codeleted oligodendrogliomas respond favorably to specific chemotherapy regimens.
Determining molecular subtype currently requires tissue obtained through biopsy or surgical resection, followed by immunohistochemistry, fluorescence in situ hybridization (FISH), or next-generation sequencing. This process introduces delays of days to weeks and is not available in all clinical settings, particularly in resource-limited environments. The ability to predict molecular subtype non-invasively from MRI -- a modality that is universally available in preoperative neuro-oncology workup -- would represent a meaningful advance for treatment planning and patient counseling.
Previous studies have shown that certain MRI features correlate with molecular status. IDH-mutant tumors tend to be located in the frontal lobe, exhibit homogeneous signal on T2-weighted imaging, and show less contrast enhancement than their wildtype counterparts. However, these imaging signs are neither sensitive nor specific enough for reliable individual-patient prediction. Machine learning methods offer the potential to capture complex, multivariate imaging patterns that go beyond what qualitative radiological assessment can achieve.
Methodology
This study used a cohort of glioma patients with both preoperative MRI data and confirmed molecular typing from surgical specimens. The MRI protocol included standard clinical sequences: T1-weighted, post-contrast T1, T2-weighted, and T2-FLAIR. Tumors were segmented on imaging, and a set of quantitative features was extracted from the segmented regions, including intensity-based statistics, texture features (such as those derived from gray-level co-occurrence matrices), shape descriptors, and features capturing the spatial relationship between the tumor and surrounding brain structures.
We evaluated multiple machine learning classifiers, including random forests, gradient-boosted trees, and support vector machines, to predict molecular subtypes from the extracted feature sets. Feature selection was performed to identify the most informative imaging biomarkers and reduce dimensionality, which is particularly important given the relatively small sample sizes typical of single-center neurosurgical cohorts. The classification targets included IDH mutation status (mutant vs. wildtype) and, where data permitted, the combined IDH/1p19q molecular groupings that define the current WHO taxonomy.
All models were evaluated using stratified cross-validation to account for class imbalance and ensure that performance metrics reflected true generalization. We reported AUC-ROC, sensitivity, specificity, and positive predictive value. Additionally, we analyzed which imaging features contributed most to the classification decisions, providing insight into the radiological correlates of molecular subtype that the models captured.
Results
The machine learning classifiers achieved encouraging accuracy in predicting IDH mutation status from preoperative MRI features. The best-performing models showed strong discriminative ability, with AUC-ROC values that exceeded the performance of qualitative radiological assessment based on individual imaging signs. The combination of texture features, intensity statistics, and tumor location information proved to be particularly informative, consistent with the known radiological literature on IDH-mutant glioma characteristics.
Among the features most predictive of IDH status, tumor location relative to the frontal lobe, the degree of contrast enhancement, and specific texture properties on T2-FLAIR sequences ranked highly. These findings are biologically plausible: IDH-mutant gliomas are known to arise preferentially in the frontal lobe, tend to enhance less, and often present with more homogeneous signal characteristics. The models thus learned to exploit these established associations while also capturing more subtle multivariate patterns that are difficult for human readers to assess simultaneously.
Prediction of the full three-class molecular subtyping (IDH-wildtype, IDH-mutant without 1p/19q codeletion, and IDH-mutant with 1p/19q codeletion) was more challenging, as expected given the finer granularity and smaller per-class sample sizes. Nevertheless, the results were sufficient to demonstrate feasibility and identify the imaging features that best distinguish these groups. The work established a foundation for larger-scale validation studies that could move non-invasive molecular typing closer to clinical deployment.
Clinical Applications
- Pre-surgical planning: Better informed treatment strategies, enabling surgeons and oncologists to anticipate likely molecular subtype before tissue is available
- Non-invasive subtyping: Molecular classification without biopsy, particularly valuable in cases where surgical access is limited or biopsy carries elevated risk
- Prognosis prediction: Early outcome estimation based on predicted molecular status allows for more nuanced patient counseling at the time of initial diagnosis
Non-invasive molecular typing has the potential to reshape the early stages of glioma management. By providing a probabilistic estimate of molecular subtype at the time of initial MRI, clinicians could stratify patients for different treatment pathways before surgery, prioritize operating schedules based on predicted tumor aggressiveness, and begin informed discussions with patients about expected outcomes. As molecular classification becomes increasingly central to neuro-oncology, the clinical value of imaging-based prediction tools will only grow. Future directions include deep learning approaches operating directly on raw imaging data, multi-institutional validation, and integration with other non-invasive biomarkers such as circulating tumor DNA.